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Recent findings suggest that pain and pleasure share common neurochemical circuits, and studies in animals and humans show that
opioid-mediated descending pathways can inhibit or facilitate pain. We explored the role of endogenous opioid neurotransmission in
pleasure-related analgesia. -Opioidergic activity was blocked with 0.2 mg/kg naloxone to assess its effects on hedonic responses to
pleasant emotional pictures (International Affective Picture System) and itsmodulating effects on heat pain tolerance. Naloxone did not
alter subjective and autonomous reactions to pleasure induction or overall mood of participants. In addition, pleasure-related increases
in pain tolerance persisted after reversal of endogenous-opioidergic neurotransmission. Subjective pain intensity and unpleasantness
ratings increased after naloxone administration. These findings suggest that, in addition to opioid-sensitive circuits, mainly opioid-
insensitive pain-modulating circuits are activated during pleasure-related analgesia.
Introduction
Pain and pleasure appear to be at opposite ends of a single scale
(Leknes and Tracey, 2008). However, we often experience situa-
tions where both sensations are intertwined. For example, pain
can enhance pleasure while eating spicy food (Rozin and Schiller,
1980). Also, positive affective states decrease pain perception (de
Wied and Verbaten, 2001; Meagher et al., 2001; Rainville et al.,
2005; Kut et al., 2007; Lewkowski et al., 2008; Roy et al., 2009;
Villemure and Bushnell, 2009). Yet the neural underpinnings of
pleasure-related analgesia have hardly been explored and clearly
deserve more attention.
Recent studies in animals and humans show that an opioid-
mediated descending pain system can inhibit or facilitate pain
(Fields, 2004). Altered -opioid receptor availability has been
found in brain regions thought to be mainly involved in mediat-
ing the affective components of pain (Zubieta et al., 2001;
Sprenger et al., 2006). Moreover, there is important evidence on
the involvement of -opioid neurotransmission in attentional
and cognitivemodulation (e.g., placebo effect) of pain (Benedetti
et al., 2005; Tracey andMantyh, 2007; Enck et al., 2008; Wiech et
al., 2008). Pain modulation by means of context, expectancy, or
attention is regulated, at least in part, by descending and opioid-
sensitive modulatory circuits (Petrovic et al., 2002; Colloca and
Benedetti, 2005) and, in addition, by the direct effects of opioids
upon cortical nociceptive-related areas (e.g., anterior cingulate
cortex) (Petrovic et al., 2002).
The mood-elevating effects of opiates have been known
and used for millennia. After comprehensive research in mice
(Panksepp, 2003; Burgdorf and Panksepp, 2006; Fields, 2007),
increasingly, imaging studies are examining the involvement
of opioidergic neurotransmission in the regulation of affective
states in humans. For example, whereas sustained sadness was
associated with a deactivation in -opioid neurotransmission
(Zubieta et al., 2003), euphoric mood states were inversely cor-
related with opioid binding in prefrontal/orbitofrontal cortices
(Boecker et al., 2008).Moreover, opioids seem to be implicated in
the hedonic response to pleasant sensory and emotional stimuli,
such as sweet taste (Berridge, 2003; Pecin˜a, 2008) or visual stimuli
(Gospic et al., 2008).
Until now, investigations have mostly explored the role of
opioid neurotransmission in both phenomena in isolation but
not in their interaction (Leknes and Tracey, 2008). Recently, it
has been shown that naloxone blocking of the pain-inhibitory
circuit involving opioid-rich areas enhances the acquisition of
conditioned fear in humans to brief pain stimuli of the kind we
have used here (Eippert et al., 2008). In addition, a general circuit
bridging pain and reward networks has been suggested for the
processing of aversive and rewarding information (Becerra et al.,
2001). Bearing this in mind, we hypothesized that pleasant affective
states will be associated with enhanced opioidergic neurotransmis-
sion, contributing to reduced pain perception. Further, we hypoth-
esized that mood-elevating pictures would alter pain intensity and
unpleasantness. To assess the effects of endogenous opioids upon
pleasure-related analgesia, we used naloxone, a predominantly
-opioid-receptor antagonist that temporarily reverses the ef-
fects of -opioidergic activity (Amanzio and Benedetti, 1999).
We investigated whether the reversal of-opioidergic activity by
means of naloxone can attenuate the hedonic response to pleas-
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ant emotional pictures [International Affective Picture System
(IAPS)] and reduce pleasure-related analgesia. In particular, we
analyzed the effects of naloxone during pleasure induction on
heat pain tolerance, subjective pain intensity and unpleasantness,
self-reports on valence and arousal of experienced affective states,
autonomic reactions (startle magnitude and skin conductance
level) and overall mood.
Materials andMethods
Participants. Twenty-two healthy right-handed male volunteers (mean
age, 26.5 years; range, 19–44)were included in the study. All participants
had normal pain thresholds at the site of stimulus application (Yarnitsky
et al., 1995; Schaffner et al., 2008), no history of neurological or psychi-
atric disease or drug abuse, no history of chronic or acute pain, and were
not taking any form of analgesic, antidepressant, anti-anxiety or antihy-
pertensive medication. Participants were asked to refrain from alcoholic
beverages 12 h before the experiment. Handedness was determined using
a standard handedness inventory (Chapman and Chapman, 1987). The
study was conducted in accordance with the Declaration of Helsinki on
the treatment of human subjects and was approved by the local research
ethics committee and federal authorities. All participants gave written
informed consent before participating in the study andwere free to with-
draw from the study at any time. They were instructed about the double-
blind administration of naloxone and informed that no side effects
were expected at the doses used. In addition, participants were told
that the administered substance could increase, decrease, or not alter
pain perception.
Drug administration.Participantswere randomly assigned in a double-
blind manner to either a naloxone or a control group. An intravenous
catheterwas placed in the antecubital vein of the nondominant armat the
beginning of the experimental session. In between blocks, participants in
the naloxone group were administered naloxone hydrochloride (0.2 mg/
kg; concentration 1 mg/ml) and subjects in the control group an equiva-
lent volume of saline (0.9% NaCl). Similar naloxone dosages have been
previously shown to completely antagonize endogenous opioid-mediated
analgesia in healthy volunteers (Amanzio and Benedetti, 1999).
Emotional stimuli.We used a standardized selection of highly pleasant
emotional stimuli from the IAPS (Lang et al., 2004). These pictures have
been shown to robustly induce positive affective states and pleasure-
related analgesia (deWied andVerbaten, 2001;Meagher et al., 2001). For
each block, a set of 15 pictures was selected (picture sets 1 and 2). Care
was given to ensure that both sets of pictures were equivalent in mean
normative valence and arousal ratings for male subjects (picture set 1:
valence mean, 7.58; SD, 1.43; arousal mean, 6.56; SD, 2.01; picture set 2:
valence mean, 7.38; SD, 1.39; arousal mean, 6.28; SD, 2.00). Stimuli
consisted mainly of erotic (couples in erotic poses, nude females) and
sports pictures. According to the motivational priming hypothesis by
Lang and coworkers (1990), erotic pictures, having great motivational
relevance, lead to strong appetitive system activation and arousal (Brad-
ley et al., 2006). IAPS slide numbers for the two picture sets used were as
follows: picture set 1: erotic: 4220, 4225, 4641, 4651, 4659, 4670, 4680;
sports: 5621, 5626, 8080, 8186, 8190, 8499, 2071, 8501; picture set 2:
erotic: 4250, 4599, 4611, 4652, 4653, 4658, 4660, 4695; sports: 8170, 8185,
8200, 8370, 8496, 2303, 7330. To control for position effects, the two
picture sets were presented in counterbalanced order. Pictures in each set
were presented in randomized order for 6 s followed by a white screen as
interpicture interval that lasted for either 2 or 12 s, resulting in a total set
length of 180 s. Participants were asked to attentively watch the pictures,
let the pictures affect them, and to be open to imagining themselves as
part of the shown situationwhen appropriate. A practice block consisting
of two pictures was used to familiarize participants with the type of
pictures theywere about to see. Pictures were presented on a 19”monitor
placed70 cm away from participants.
Pain stimuli.Noxious heat stimuli were administered using a 30 30
mm Peltier device (TSA-II; Medoc) placed on the volar aspect of the
nondominant forearm. Pain threshold was measured at the beginning of
the experiment: volunteers were asked to stop the heat stimulus when
they felt it turning from “hot” to “painful.” For individual pain toler-
ances, participants were asked to stop the increasingly painful stimulus at
the point they could not stand it any longer. Pain threshold and pain
tolerances were determined by calculating the average of three measure-
ments starting at 35°C with a constant rise of temperature (0.8°C/s). To
avoid physical injuries, the heating device was preprogrammed so that it
stopped automatically at a maximum temperature of 52°C. To diminish
visual distraction, participants were asked to close their eyes during the
full length of painmeasurements. For pain tolerancemeasurements right
after picture presentation, we asked participants “to remain in the affec-
tive state they experienced while looking at the pictures.”
Autonomic reactivity. Skin conductance level (SCL) and startle blink elec-
tromyographic (EMG) response weremeasuredwith an eight-channel Var-
ioportmeasurement system (BeckerMeditec) andwere saved on a compact
flash card for off-line analyses. Sampling rate was set to 256 Hz for SCL and
to 1024 Hz for EMG recordings. Skin conductance electrodes (Ag/AgCl, 5
mm contact area diameter; Marquette Hellige Medical Systems) filled with
lubricating jelly (SCL-Paste, 0.5%NaCl; Becker Meditec) were placed adja-
cently on thehypothenar eminence of the palmof the nondominant hand,
which was cleansed in advance with distilled water. SCL raw data of each
participant was amplified, dedrifted, rectified, and averaged throughout
the picture-viewing periods in each block (180 s). Startle blink responses
were recorded from the orbicularis oculi muscle beneath the left eye,
using two 4 mm Ag/AgCl electrodes placed 1.5 cm apart and a ground
electrode placed on the mastoid bone following guidelines by Blumen-
thal et al. (2005). Startle responses were elicited by a 50 ms, 90 dB(A)
burst of white noise with instantaneous rise time presented binaurally
over Philips SBCHP195 headphones. For each block, blink magnitudes
of three startle probes presented during picture viewing were averaged;
nonresponses were scored as zero magnitude blinks (13 of 132 blinks).
Startle probes were presented 3000 ms after picture onset.
Subjective ratings. Subjects rated their pain intensity and unpleasant-
ness on two consecutive visual analog scales (VASs) with the endpoints
“no pain” and “worst pain experienced,” and “neutral” and “extremely
unpleasant,” respectively. The VASs were presented on amonitor screen.
Participants gave their ratings by mouse clicking the pursuant position
on the VAS. The obtained ratings were then transformed into scores
between0and10.Toassesswhether the inductionof apositive affective state
was effective, and to estimatewhethernaloxone alteredhedonic responses to
pleasant emotional stimuli, participants gave ratings regarding valence and
arousal of the affective state they experienced on a computerized SAM (self-
assessmentmanikin questionnaire). The formulated questions were, for va-
lence: “How pleasant or unpleasant were your feelings while watching the
pictures?”and, forarousal, “Howarousingwereyour feelingswhilewatching
the pictures?” The SAMconsisted of two sets of five pictographs depicting
different levels of affective valence and arousal (Lang, 1980). Subjects
were asked to click with the cursor on or between the figures. For each
dimension, ratings between 1 and 9 were recorded. Ratings were scored
such that 9 represented a high rating on each dimension. The manipula-
tion check to verify emotional induction was conducted after the pain
ratings to minimize possible demand or expectation effects (Meagher et
al., 2001). To assess the influence of naloxone onmood, theMehrdimen-
sionaler Befindlichkeitsfragebogen (MDBF; Multidimensional Mood
State Questionnaire) (Steyer et al., 1997) was used at the start and at the
end of the experiment. It included adjectives for the dimensions “feeling
well versus not well,” “feeling alert versus tired,” and “feeling calm versus
aroused.” For each dimension, ratings between 1 and 5 were recorded.
Ratings were scored such that 5 represented a high rating on each dimen-
sion (e.g., well, alert, and aroused). The two parallel versions of the ques-
tionnaire were given to participants in counterbalanced order. At the end
of the experimental session, participants answered whether they believed
having received naloxone or saline by clicking a pursuant check box on
the monitor.
Experimental procedure. At the beginning of each experimental ses-
sion, participants were screened for medical problems (self-report) and
were told that the main aim of the study was evaluating the impact of
emotional pictures on the individual affective state. To prevent partici-
pants from focusing on the painful stimuli, and to focus their attention
on pleasure induction, the occurrence of noxious heat stimuli was men-
tioned but not as a principal study goal. After determining the weight of
Kut et al. • Pleasure-Related Analgesia and-Opioid Receptors J. Neurosci., March 16, 2011 • 31(11):4148–4153 • 4149
volunteers and the insertion of an intravenous
catheter, participants were seated in front of a
monitor in a dimly lit room. The experimenter
affixed the thermode and the electrodes for au-
tonomic reaction measurements and asked
participants to follow the instructions pre-
sented on the computer screen (SuperLab 4.0).
The experiment was divided into two blocks
(Fig. 1). In each block, one of the two picture
sets was presented. Right before and after pic-
ture presentation, pain tolerance succeeded by
subjective pain ratings (VAS) was assessed. At
the end of each block, participants rated the
affective state they had experienced while
watching the pictures (SAM). Right before
block 1, and immediately after block 2, mood
ratings were assessed (MDBF). In between
blocks, naloxone or saline was administered.
Special care was given so that participants did
not feel any pain or worry about the procedure.
While waiting for the onset of naloxone effects
after intravenous administration (2 min)
and to distract subjects from the just experi-
enced drug administration, a short (3 min) geometrical task was dis-
played on the monitor (meaningless geometric figure pairs had to be
judged for similarity).
The experiments were performed according to a randomized double-
blind design. For safety reasons (potential unforeseen side-effects of nal-
oxone), the experimenter and the medical doctor stayed behind a
partition in the same room. To control for confounding factors associ-
ated with circadian variations and the experimenter’s presence, all par-
ticipants were tested in the afternoon and by the same experimenter. At
the end of an experimental session (total duration,70min), volunteers
were debriefed about the experimental aims and received a monetary
compensation for their participation in the study.
Dataanalysis.Forpain tolerancemeasurements,pain, andemotional ratings,
repeated-measures ANOVAs were performed. Within-subject factors were
block (block 1: before injection vs block 2: after injection) and time (before
pictureviewingvs afterpictureviewing),withgroup(naloxonevs control) as
a between-subject factor. p values in the ANOVAs and t tests were corrected
using Greenhouse–Geisser and Bonferroni correction, respectively. Post hoc
comparisons were performed using two-tailed Student’s paired t tests. Cor-
relationsbetweenskinconductance levelswere calculated separately forboth
groups using Pearson’s correlation coefficient. In the analysis of subjective
pain ratings, Grubb’s test for outliers uncovered one outlier, which was
therefore excluded fromVAS analyses. Significance level was set at p 0.05
for all statistical calculations.
Results
Expectation
Seventy-seven percent of the study participants believed they had
received saline. Two participants who thought they had received
naloxone were in the naloxone group and the other three were in
the control group.
Pain tolerance
The repeated-measures ANOVAwith the factors group, block,
and time was significant for the factor time; after picture view-
ing tolerances were higher (F(1,20)  29.61, p  0.000). The
factor block was also significant; tolerances were lower in
block 2 (F(1,20)  16.82, p  0.001). The block-by-time inter-
action was significant as well (F(1,20) 18.54, p 0.000) (Fig.
2). Post hoc t tests confirmed that pain tolerance increased
significantly after picture viewing for both blocks (block 1:
t(21)  2.94, p  0.008; block 2: t(21)  5.67, p  0.000),
but decreased after injection [(block 1 pre-picture viewing)
(block 2 pre-picture viewing); t(21)  4.70, p  0.000]. No
other effects were significant, suggesting that naloxone influ-
enced neither pain tolerance nor pleasure-related analgesia.
Pain ratings
For pain intensity, a significant effect found for the factor block was
that pain intensity ratings were higher after injection (F(1,19) 5.35,
p 0.032). Both scales showed a significant block-by-group inter-
action (intensity: F(1,19) 4.52, p 0.047; unpleasantness: F(1,19)
4.31, p 0.050). Post hoc t tests uncovered that the naloxone group
gave higher pain ratings after injection (intensity: t(10)3.48, p
0.006; unpleasantness: t(10)  2.57, p  0.028), whereas control
group ratings did not change significantly (intensity: t(9)0.120,
p 0.91; unpleasantness: t(9) 0.122, p 0.91) (Fig. 3). No other
effects were seen.
Picture ratings
Data for blocks 1 and 2 confirm that the picture sets induced the
targeted pleasant affective state (mean valence, 7.5; mean
arousal,5.5). For SAMvalence, we found a significant effect for
Block 1 Block 2
Figure 1. Schematic depiction of an experimental session consisting of two blocks. Each block (13 min in length) included
pain-tolerance measurements before and after a period of picture viewing consisting of 15 pleasant IAPS pictures (180 s in total).
Pain-tolerancemeasurements were followed by subjective pain ratings. At the end of each block, subjective ratings on emotional
state during picture viewing were collected. In between blocks, drug was administered, followed by a 3 min distraction task. Red
bars represent the use of noxious heat stimuli and their associated pain-tolerance measurement. Vertical arrows represent scales
and questionnaires displayed on a computer screen. Autonomic reactivity was measured during picture viewing periods in which
three acoustic startle stimuli were presented (grouped vertical arrows).
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the factor block, but not for arousal ratings (valence: F(1,20) 
6.43, p  0.02; arousal: F(1,20)  0.030, p  0.87). The valence
ratings for the affective state decreased in block 2, yet still mir-
rored highly pleasant states (mean, 6.8). We found no block-
by-group interaction for either scale, suggesting that naloxone
did not alter hedonic responses to pleasant visual stimuli. Affec-
tive state ratings for block 1 did not differ depending on picture
set 1, indicating that the emotional impact of both picture sets
was equivalent (independent samples t test for valence and
arousal, p 0.27).
Autonomic reactivity
Averaged SCLs throughout the picture viewing periods were not
significant for the factor block, nor the block-by-group interac-
tion (both p  0.46). Conversely, correlation analyses between
skin conductance levels in block 1 and block 2 were significant in
both groups (control:  0.471, p 0.001; naloxone:  0.484,
p  0.001), confirming that hedonic response, in terms of SCL,
was not affected by naloxone. Analogously, averaged startle mag-
nitudes during pleasure induction were not significantly altered
by blockade of endorphinergic activity (block and block-by-
group, p 0.13).
Mood
The factor scale was significant (F(1,20) 3.52, p 0.050), whereby
post hoc t test of scale ratings did not survive Bonferroni corrections,
suggesting that ratings for “feelingwell versusnotwell,” “feelingalert
versus tired,”and“feelingcalmversusaroused”didnotdiffer.More-
over, the block-by-time and block-by-group interactions were not
significant (both p 0.19), indicating thatmoodwas constant dur-
ing the experiment, uninfluenced by naloxone.
Discussion
Our study examined the contribution of endogenous opioids in
emotional painmodulation.We hypothesized that enhanced opioi-
dergicneurotransmissionduringpositive affective states contributes
to pleasure-related analgesia. Contrary to our expectations, hedonic
response to pleasant visual stimuli and altered pain tolerances were
insensitive to naloxone. Subjective pain intensity and unpleasant-
ness ratings increased after naloxone injection.
Positive affective states are associated with enhanced opioidergic
activity (Boecker et al., 2008; Koepp et al., 2009) and negative states
with its deactivation (Zubieta et al., 2003). Also, the hedonic re-
sponses to external emotional stimuli, such
as sweet taste (Berridge, 2003), IAPS pic-
tures (Gospic et al., 2008), andmonetary re-
ward (Petrovic et al., 2008), were shown to
be modulated by opioids. In our study,
mood and subjective ratings of experienced
affective states during pleasant-picture
viewingwere not significantly influenced by
naloxone. Corroboratively, skin conduc-
tance responses, consistently shown to co-
vary with arousal judgments (Lang et al.,
1990), and the magnitudes of acoustically
elicited startle eye blinks, a reliable marker
for the valence of an affective state (Lang et
al., 1990), remained unchanged. Current
hypotheses suggest that analgesia induced
by viewing emotionally loaded pictures
grounds on effects from changes in affective
state and covariate, hardly dissociable atten-
tional processes (Villemure and Bushnell,
2002). Since subjective and autonomic reac-
tions to pleasure induction and overall mood neither differed be-
tween groups nor changed during the experiment, we suggest
that the degree of attention was equivalent among
participants.
Many studies have identified a major role of the endogenous
opioid system in pain modulation by reversing its effects with
naloxone (Gracely et al., 1983; Amanzio and Benedetti, 1999;
Eippert et al., 2008) and using molecular imaging techniques
(Zubieta et al., 2005; Scott et al., 2008). Our findings show that
pleasure-related analgesia, measured as an increase in pain toler-
ance, was insensitive to naloxone injection. After substance ad-
ministration, we found a substance-unspecific decrease in pain
tolerance. It is probable and even likely that the procedure of drug
administration (pressure in the vein) was responsible for these
results. In line with previous findings on the effects of naloxone
on heat-painmeasurements, the increased level of subjective pain
ratings of intensity and unpleasantness was substance specific
(Borras et al., 2004). This result is highly appealing, as it suggests
that -opioidergic neurotransmission is involved in the subjec-
tive response to heat pain. Because pain tolerances after pleasure
induction were not attenuated by naloxone, it can be assumed
that a major involvement of opioid-insensitive inhibitory sys-
tems is at work here. Studies on stress-induced analgesia and on
placebo analgesia have similarly proposed the existence of
opioid-sensitive and opioid-insensitive descending modulatory
systems (Amanzio andBenedetti, 1999; Flor et al., 2002; Ford and
Finn, 2008). Several neurotransmitter systems, including dopa-
minergic, serotonergic, cannabinergic, and monoaminergic,
have been shown to play a role in endogenous pain inhibition,
but there is still a need for research on these systems (Millan,
2002). Although highly speculative, we consider dopamine sig-
naling as a potential candidate able to preserve hedonic process-
ing in the absence of opioid mediation. Along this line of
reasoning, a recent review of the literature has shown a key role of
dopamine on pain perception in humans, suggesting its involve-
ment in endogenous pain modulation systems (Potvin et al.,
2009). In addition, pleasure and reward expectation have been
associated with increased phasic dopamine signaling (Schultz,
2010). Even if the precise role of dopamine in pain and reward is
far from unequivocal (Leknes and Tracey, 2008), and its function
varies at different time courses (Schultz, 2007), some recent evi-
dence suggests a possible opioid-independent dopaminergic me-
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Figure 3. A, B, Mean VAS pain-intensity ratings (A) and mean VAS pain-unpleasantness ratings (B) in block 1 (before drug
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diation of hedonic processes (Scott et al., 2008). It is important to
also consider the potential role of endocannabinoids for the pres-
ent results, as they have been related to nondrug rewarding be-
haviors (Fattore et al., 2010) and in analgesia (Guindon and
Hohmann, 2009). Notably, substantial and complex interactions
between endocannabinoid systems and opioids in nociception
(Welch, 2009) and dopamine in the processing of motivationally
salient information have been described (Laviolette and Grace,
2006). But the interactions are complex and future studies will be
needed to further elucidate a separate or cojoint action of these
systems in the processing of reward-related analgesia. From a
homeostatic perspective, the fact that reversal of endogenous
-opioid neurotransmission did not significantly alter—at least
at the behavioral level—hedonic processing and pain inhibition
is comprehensible. The notion that both of them are maintained
by different complementing, interacting, and overlapping neural
and chemical modulatory circuits, quickly equilibrating external
disturbances, seems quite compelling if affective processes are
conceptualized as action dispositions able to regulate and opti-
mize an individual’s response to motivationally relevant stimuli
(Lang et al., 1990).
Three methodological caveats limit the interpretation of our
results. First, we measured effects of naloxone on hedonic and
pain responses 3 min after bolus administration. We decided to
use a short measurement window, compared with other studies,
since naloxone is well known for its rapid onset of action, rate of
elimination, and distribution being administered in clinical set-
tings in 2–3 min intervals (Ngai et al., 1976; Goldfrank et al.,
1986). Although this methodological limitation does not allow
for verification of complete receptor blockage by the time ofmea-
surement, the significant effects of naloxone on subjective pain
ratings support at least a partial blockage of endogenous pain-
modulatory mechanisms. Bearing this in mind, it should be ex-
pected that having a peak blockage of opioid receptors by using a
longer time window would result in even stronger effects. Sec-
ond, we observed a decrease of subjective valence ratings in block
2 that was group independent and most probably due to habitu-
ation effects. This might have resulted in a floor effect preventing
naloxone from producing any further changes in valence and
arousal. One could argue that viewing pleasant photographs,
mostly erotic in nature, within an experimental settingmight not
have changed the basal level of endogenous opioids, leaving
blockage of-opioid receptors without any consequences. How-
ever, this would imply a negligible role of -opioidergic neu-
rotransmission in hedonic processing since participants clearly
experienced positive affective states. Alternative interpretations
are possible. It might be that with our experimental design,
changes in opioid neurotransmission in core processes of positive
affective reaction might have happened, but at levels far too low
to be detectable at behavioral levels. Future studies using stronger
pleasure-inducingmethods, and thus presumably involving pro-
nounced endogenous opioid release, might reveal larger antago-
nizing effects. The inclusion of neutral affective stimuli in these
experimental designs will likely improve the explanatory power
of the reported findings. Third, we measured a small sample size,
which advises for a cautious interpretation of our results. How-
ever, we firmly believe that this study provides preliminary yet
clear evidence for opioid-sensitive and opioid-insensitive com-
ponents of affective regulation and modulation of pain experi-
ences. Future studies using more sensitive measurement
techniques focusing on molecular endogenous opioid peptides
may also contribute to deepen our understanding of the effects of
opioid-insensitive components of affective regulation. Undoubt-
edly, the further understanding of the neurobiological underpin-
nings of pleasure-related analgesia will be of great benefit for the
clinical management of pain.
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